Table 5. Vaccinations Prior to or After Solid Organ Transplant
Recommendation
(Strength, Evidence Quality)
Vaccine Pretransplant
Starting 2–6 Months
Posttransplant
H influenzae type b
conjugate
U (SR-M) U (SR-M)
Hepatitis A U: age 12-23 mo (SR-M)
R: age ≥2 y (SR-M)
R, if not completed
pretransplant (SR-M)
Hepatitis B U: age 1-18 y (SR-M)
R: age ≥18 y (SR-M)
R, if not completed
pretransplant
a
(SR-M)
DTaP, Tdap U (SR-M) U, if not completed
pretransplant (SR-M)
HPV U: females age 11-26 y
(SR-M)
U: females age 11-26 y
(SR-M)
U: males age 11-26 y (SR-L)
Influenza, inactivated U (SR-M) Ub (SR-M)
Influenza, live attenuated X (WR-L) X (WR-L)
MMR, live R
c
: age 6-11 mo (WR-VL)
U
d
: age ≥12 mo (SR-M)
X (SR-L)
MMRV, live U
d
(SR-M) X (SR-L)
Meningococcal conjugate U (SR-M) U (SR-M)
Pneumococcal conjugate
(PCV13)
U: age <5 y (SR-M)
R: age ≥6 y
e
(SR-VL)
U: age 2-5 y (SR-M)
R: age ≥6 y, if not
administered pretransplant
e
(SR-VL)
Pneumococcal
polysaccharide (PPSV23)
R: age ≥2 y (SR-M) R: age ≥2 y, if not
administered pretransplant
(SR-M)
Poliovirus, inactivated U (SR-M) U (SR-M)
Rotavirus, live U
c
(SR-M) X (SR-L)
Varicella, live R
f
: age 6-11 mo (WR-VL)
U
d
(SR-L)
X
g
(SR-L)
Zoster, live R
h
: age 50-59 y (WR-L)
U
i
: age ≥60 y (SR-M)
X (SR-L)
23
Continued on next page
